Sindy T. Kim

Texas Oncology — United States

Medicine · Health Sciences

18h-index14.2kcitations35works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(26), Renal and related cancers(8), Cancer Genomics and Diagnostics(6), Pancreatic and Hepatic Oncology Research(5), Economic and Financial Impacts of Cancer(5)

Publications35 total

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology·2023· 164 cited
Supplementary Table 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Figure 3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Figure Legends 1-3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Data from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Table 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Figure Legends 1-3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Data from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Figure 2 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Figure 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Figure 3 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Figure 2 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Supplementary Figure 1 from Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
2023Open Access
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
Breast Cancer Research·2016· 180 citedOpen Access
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
Leukemia & lymphoma/Leukemia and lymphoma·2015· 65 cited
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
The Lancet Oncology·2014· 1.9k cited
Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
Cancer Research·2014· 51 cited
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
Cancer Chemotherapy and Pharmacology·2013· 59 citedOpen Access
Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Clinical Cancer Research·2012· 66 citedOpen Access
Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma
Blood·2011· 4 cited
page 1 of 2Next →

Frequent Co-authors

Robert J. Motzer(25), Xin Huang(13), Wilfred D. Stein(13), Julia Wilkerson(13), Antonio Tito Fojo(13), Susan E. Bates(13), M. Dror Michaelson(9), Isan Chen(9), Xin Huang(7), Thomas E. Hutson(6), Ronald M. Bukowski(6), Robert A. Figlin(6), Sophia Randolph(6), Sylvie Négrier(5), George Wilding(5), Charles M. Baum(4), Gary R. Hudes(4), Jim Z. Li(4), Brian I. Rini(4), Claudie Charbonneau(4)